The Oncology Institute, Inc.
STLNHealthcareNASDAQMedical Care Facilities
Scan Results
Daily timeframeOperating under the Medical Care Facilities umbrella, The Oncology Institute, Inc. is a healthcare company. Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. The $644.1M market capitalization puts STLN squarely in small-cap range for its industry. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other.
Market Cap
$644.1M
Beta
0.44
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.29
EPS (Fwd)
—
ROE
—
ROA
-9.7%
Cash
$41.1M
Total Debt
$104.8M
Free CF
$8.6M
52W Change
89.5%
Annual Financials
Cash vs Debt
Where STLN stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, STLN finished 39.44% above its 150-day moving average ($4.26) and 45.95% above its 200-day moving average ($4.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is STLN overbought or oversold?
At the September 2, 2026 close, STLN's RSI(14) was 42.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $41.1M in cash, though total debt stands at $104.8M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $8.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Revenue has grown from $252.5M (2022) to $502.7M (2025), reflecting a 99% increase over the period.
The relatively low beta of 0.44 suggests STLN is a less volatile holding compared to the broader index. No single metric tells the full story. Reviewing STLN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.